These oil stocks have bottomed
watch now

Excited that earnings season is back in full swing, Jim Cramer is already gearing up for next week. However, given the volatility in Europe this week, he still subscribes to his "America First" theory. Forget about foreign stocks; he is sticking to the land of money-making opportunity. And that is the U.S.A. until further notice, inclusive of oil stocks that may have bottomed this week.

"You need to see oil stabilize, and you need to see the consumer finally recognize that gasoline's not going to back up to $4 a gallon any time soon, to encourage buyers to start taking advantage of some of the incredible bargains this week's selloff has created," the "Mad Money" host said. However, Cramer maintains that we are in a trader's market. It is only as good as the country, company or person who last spoke. That is why earnings are crucial next week—they will determine the direction of the market. A few companies he will be watching next week include Verizon , Halliburton , Netflix and General Electric . Read More Cramer's game plan: It all depends on this



Cultura Science | Rafe Swan | Getty Images

This week Cramer has been highlighting the hottest biotech stocks for 2015 as a part of his series, "Biotech, the Next Generation." One of the best performing biotechs for 2014 was the orphan- drug company PTC Therapeutics , which rallied 205 percent last year. PTC focuses on rare genetic disorders, especially those caused by nonsense mutations in DNA. Its main drug is Translarna, approved in the EU for Duchenne muscular dystrophy (DMD) and could launch in the U.S. next year. To find out if this company can keep pulling in profits for 2015, Cramer sat down with PTC Therapeutics Chief Financial Officer Shane Kovacs.

"Last year was a monumental year for us, because the European authorities approved our drug. This is the first approval ever in this disease for the underlying cause," Kovacs said.

Read More Cramer: The biotech that doubled in value last year

Another hot biotech on Cramer's radar this year is Relypsa . This company is focused on developing treatments for kidney, cardiovascular and metabolic disorders. One of its main developments is Partiromer that treats hyperkalemia, which refers to high potassium levels. Though Cramer does consider Relypsa to have some major upside potential, it is also a speculative stock with plenty of risk attached to it. To find out where the stock could be headed, Cramer spoke with Relypsa CEO John Orwin. "We conducted very rigorous clinical trials in hundreds of patients to demonstrate both that the product is effective in removing potassium, but also that what we saw was a tolerability profile suggesting that it can be used on a chronic daily basis," Orwin said. "So all of those things I think are important, and I think the FDA's decision not to hold a panel is encouraging."

Getty Images